(no title)
eonwe | 5 years ago
Which, as Eliezer notes, is part of the problem. That together with flexible delivery schedules in agreements mean that companies have little extra resources and incentives to invest in fast vaccine production.
For more discussion, see https://marginalrevolution.com/marginalrevolution/2021/02/ma...
No comments yet.